Filing Flows › Xeris Biopharma Holdings (XERS) › Q1 2025
Xeris Biopharma Holdings (XERS) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Xeris Biopharma Holdings (XERS) reported revenue of $60.1M for the first quarter 2025 (Q1 2025), +48% from a year earlier and 0% from the quarter before. Operating margin was -5.1%, net loss $9.2M (15.3% of revenue).
Xeris Biopharma Holdings, Q1 2025: revenue $60.1M (+48% year over year), operating margin -5.1%, net loss $9.2M, operating cash flow −$10.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $60.1M | 0% | +48% |
| Operating profit | −$3.1M | — | — |
| Net earnings | −$9.2M | — | — |
| Operating cash flow | −$10.0M | — | — |
What changed
Revenue was $60.1M in Q1 2025, up 48% year over year and roughly flat from the previous quarter. Recorlev was the largest line at 42% of revenue. Recorlev added $14.9M year over year (up 141%), 77% of the total change. Keveyis declined 13%.
Operating costs exceeded revenue by $3.1M, an operating margin of -5.1%. Total costs grew 15% against revenue growth of 48%. The fastest-growing cost line was Cost of revenue (+46%). The quarter ended with a net loss of $9.2M, wider than the previous quarter's $5.1M loss. Net interest and other expense of $6.1M was the main reason.
Operating cash flow was −$10.0M. Non-cash charges added back $315K of depreciation and amortization and $4.4M of share-based compensation. Working capital and other items used $5.6M.
Questions
What was Xeris Biopharma Holdings' revenue in the first quarter 2025?
Xeris Biopharma Holdings (XERS) reported revenue of $60.1M for the first quarter 2025 (Q1 2025), +48% from a year earlier and 0% from the quarter before.
Was Xeris Biopharma Holdings profitable in the first quarter 2025?
Operating loss was $3.1M (-5.1% of revenue) and net loss $9.2M.